本文へ移動
cccskills
無料GitHub で公開

enda-confirm-pai-stim-test

Recommends confirmatory testing with corticotropin stimulation test in patients presenting with clinical symptoms or signs suggesting PAI (e.g., fatigue, hypotension, hyponatremia, hyperpigmentation) when the patient's condition permits safe testing. Use when a clinician identifies suggestive features and circumstances allow outpatient stimulation testing without imminent need for emergency glucocorticoids.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md3.4 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Confirm PAI Diagnosis with Corticotropin Stimulation Test

STEP 1 — Gather Information

Collect history of suggestive symptoms (fatigue, weight loss, hypotension, hyponatremia, hyperkalemia, fever, abdominal pain, hyperpigmentation, hypoglycemia in children), vital signs, baseline morning cortisol and ACTH if available, review recent glucocorticoid use, and assess for acute adrenal crisis or contraindications to testing. If the patient is hemodynamically unstable or requires immediate steroids, proceed to emergency treatment; otherwise, move to stimulation testing.

STEP 2 — Rule In / Rule Out

Is the patient’s condition stable enough to safely undergo corticotropin stimulation testing without delaying life‑saving glucocorticoids?

  • Yes: Proceed to administer the standard 250 µg cosyntropin (or ACTH) stimulation test.
  • No: Give immediate stress‑dose intravenous hydrocortisone (100 mg) and postpone confirmatory testing until the patient is stabilized.

STEP 3 — Classify or Stratify

Measure serum cortisol 30–60 minutes post‑stimulation.

  • Peak cortisol < 500 nmol/L (18 µg/dL) (assay‑specific cutoff may apply) → consistent with primary adrenal insufficiency.
  • Peak cortisol ≥ 500 nmol/L → makes PAI unlikely; consider alternative diagnoses.

STEP 4 — Decide

If the stimulation test confirms PAI (low cortisol), initiate glucocorticoid replacement (hydrocortisone 15–25 mg/day in divided doses) and assess for mineralocorticoid deficiency; if normal, investigate other causes of symptoms and avoid unnecessary steroid therapy.

Clinical Guardrails / Mimics / Pitfalls

Do not test in patients currently on exogenous glucocorticoids, as this suppresses the response; avoid reliance on basal cortisol alone; recognize that estrogen, pregnancy, critical illness, or CBG abnormalities can alter cortisol interpretation and may require adjusted cutoffs; the low‑dose (1 µg) test is reserved for corticotropin shortage and is not preferred for PAI confirmation; never delay emergency hydrocortisone in suspected adrenal crisis pending test results.

Concrete Clinical Example

A 48‑year‑old woman reports 3 months of progressive fatigue, 4 kg weight loss, orthostatic hypotension, and new hyperpigmentation of palmar creases. Morning cortisol is 190 nmol/L (borderline) and ACTH is mildly elevated. She is afebrile, hemodynamically stable, and not on steroids. A standard 250 µg cosyntropin test yields a peak cortisol of 340 nmol/L at 60 minutes (< 500 nmol/L cutoff). This confirms PAI; she is started on hydrocortisone 20 mg daily (10 mg AM, 5 mg noon, 5 mg early evening) and fludrocortisone 100 µg daily, with education on stress dosing and a steroid emergency card.

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-1710

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する